Literature DB >> 31873312

Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS.

Mariana Bravo-Hernandez1, Takahiro Tadokoro1,2, Michael R Navarro1, Oleksandr Platoshyn1, Yoshiomi Kobayashi1, Silvia Marsala1, Atsushi Miyanohara1,3, Stefan Juhas4, Jana Juhasova4, Helena Skalnikova4, Zoltan Tomori5, Ivo Vanicky6, Hana Studenovska7, Vladimir Proks7, PeiXi Chen1, Noe Govea-Perez1,8, Dara Ditsworth8, Joseph D Ciacci9, Shang Gao10, Wenlian Zhu10, Eric T Ahrens10, Shawn P Driscoll11, Thomas D Glenn11, Melissa McAlonis-Downes8, Sandrine Da Cruz8, Samuel L Pfaff11, Brian K Kaspar12, Don W Cleveland8, Martin Marsala13,14.   

Abstract

Gene silencing with virally delivered shRNA represents a promising approach for treatment of inherited neurodegenerative disorders. In the present study we develop a subpial technique, which we show in adult animals successfully delivers adeno-associated virus (AAV) throughout the cervical, thoracic and lumbar spinal cord, as well as brain motor centers. One-time injection at cervical and lumbar levels just before disease onset in mice expressing a familial amyotrophic lateral sclerosis (ALS)-causing mutant SOD1 produces long-term suppression of motoneuron disease, including near-complete preservation of spinal α-motoneurons and muscle innervation. Treatment after disease onset potently blocks progression of disease and further α-motoneuron degeneration. A single subpial AAV9 injection in adult pigs or non-human primates using a newly designed device produces homogeneous delivery throughout the cervical spinal cord white and gray matter and brain motor centers. Thus, spinal subpial delivery in adult animals is highly effective for AAV-mediated gene delivery throughout the spinal cord and supraspinal motor centers.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31873312      PMCID: PMC8171115          DOI: 10.1038/s41591-019-0674-1

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  1 in total

1.  Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS.

Authors:  Francois Gros-Louis; Geneviève Soucy; Roxanne Larivière; Jean-Pierre Julien
Journal:  J Neurochem       Date:  2010-03-14       Impact factor: 5.372

  1 in total
  23 in total

1.  Better understanding the neurobiology of primary lateral sclerosis.

Authors:  P Hande Ozdinler; Mukesh Gautam; Oge Gozutok; Csaba Konrad; Giovanni Manfredi; Estela Area Gomez; Hiroshi Mitsumoto; Marcella L Erb; Zheng Tian; Georg Haase
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2020-11       Impact factor: 4.092

Review 2.  Nuclear-Import Receptors Counter Deleterious Phase Transitions in Neurodegenerative Disease.

Authors:  Hana M Odeh; Charlotte M Fare; James Shorter
Journal:  J Mol Biol       Date:  2021-08-28       Impact factor: 5.469

Review 3.  Prionoids in amyotrophic lateral sclerosis.

Authors:  Philippe Gosset; William Camu; Cedric Raoul; Alexandre Mezghrani
Journal:  Brain Commun       Date:  2022-06-09

4.  Precision spinal gene delivery-induced functional switch in nociceptive neurons reverses neuropathic pain.

Authors:  Takahiro Tadokoro; Mariana Bravo-Hernandez; Kirill Agashkov; Yoshiomi Kobayashi; Oleksandr Platoshyn; Michael Navarro; Silvia Marsala; Atsushi Miyanohara; Tetsuya Yoshizumi; Michiko Shigyo; Volodymyr Krotov; Stefan Juhas; Jana Juhasova; Duong Nguyen; Helena Kupcova Skalnikova; Jan Motlik; Hana Studenovska; Vladimir Proks; Rajiv Reddy; Shawn P Driscoll; Thomas D Glenn; Taratorn Kemthong; Suchinda Malaivijitnond; Zoltan Tomori; Ivo Vanicky; Manabu Kakinohana; Samuel L Pfaff; Joseph Ciacci; Pavel Belan; Martin Marsala
Journal:  Mol Ther       Date:  2022-05-05       Impact factor: 12.910

Review 5.  Gene therapy for ALS: A review.

Authors:  Defne A Amado; Beverly L Davidson
Journal:  Mol Ther       Date:  2021-04-09       Impact factor: 11.454

6.  Adeno-Associated Virus-Mediated Gene Therapy in the Mashlool, Atp1a3Mashl/+, Mouse Model of Alternating Hemiplegia of Childhood.

Authors:  Arsen S Hunanyan; Boris Kantor; Ram S Puranam; Courtney Elliott; Angela McCall; Justin Dhindsa; Promila Pagadala; Keri Wallace; Jordan Poe; Talha Gunduz; Aravind Asokan; Dwight D Koeberl; Mai K ElMallah; Mohamad A Mikati
Journal:  Hum Gene Ther       Date:  2021-02-12       Impact factor: 5.695

7.  The sustained expression of Cas9 targeting toxic RNAs reverses disease phenotypes in mouse models of myotonic dystrophy type 1.

Authors:  Ranjan Batra; David A Nelles; Daniela M Roth; Florian Krach; Curtis A Nutter; Takahiro Tadokoro; James D Thomas; Łukasz J Sznajder; Steven M Blue; Haydee L Gutierrez; Patrick Liu; Stefan Aigner; Oleksandr Platoshyn; Atsushi Miyanohara; Martin Marsala; Maurice S Swanson; Gene W Yeo
Journal:  Nat Biomed Eng       Date:  2020-09-14       Impact factor: 25.671

Review 8.  Disease Mechanisms and Therapeutic Approaches in C9orf72 ALS-FTD.

Authors:  Keith Mayl; Christopher E Shaw; Youn-Bok Lee
Journal:  Biomedicines       Date:  2021-05-25

Review 9.  Adeno-Associated Viral Vectors as Versatile Tools for Parkinson's Research, Both for Disease Modeling Purposes and for Therapeutic Uses.

Authors:  Ana Fajardo-Serrano; Alberto J Rico; Elvira Roda; Adriana Honrubia; Sandra Arrieta; Goiaz Ariznabarreta; Julia Chocarro; Elena Lorenzo-Ramos; Alvaro Pejenaute; Alfonso Vázquez; José Luis Lanciego
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

Review 10.  Biomaterials in Neurodegenerative Disorders: A Promising Therapeutic Approach.

Authors:  Matteo Bordoni; Eveljn Scarian; Federica Rey; Stella Gagliardi; Stephana Carelli; Orietta Pansarasa; Cristina Cereda
Journal:  Int J Mol Sci       Date:  2020-05-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.